This report was first published by Endpoints News. To see the original version, click here
The US-headquartered, China-rooted biotech Earendil Labs said it has raised $787 million in private money, a whopping sum to fund an AI platform that has already produced a pipeline of over 40 drug programs.
Despite all of the hype and attention around AI in biotech, Earendil has stayed more under the radar. One of the lead investors in the company, Dimension Capital’s Zavain Dar, on Friday called it “the DeepSeek of biotech,” referencing the tiny Chinese startup that stunned AI giants at the start of 2025 by building competitive models with a fraction of the compute and resources.
您已阅读26%（677字），剩余74%（1916字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。